Antagonistic functional duality of cancer genes

Gene

Volumn 529, Issue 2, 2013, Pages 199-207

  Stepanenko, A A ^a   Vassetzky, Y S ^b   Kavsan, V M ^a  

^a Institute of Molecular Biology and Genetics   (United Kingdom)

^b UMR 8126   (France)

Author keywords

Aneuploidy; Chromosome instability; Genetic heterogeneity; Targeted therapy

Indexed keywords

2 HYDROXYGLUTARIC ACID; ANTINEOPLASTIC AGENT; EVEROLIMUS; IMATINIB; ISOCITRATE DEHYDROGENASE; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PLACEBO; SUNITINIB;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL LINE; CELL PROLIFERATION; CELL TYPE; CHRONIC MYELOID LEUKEMIA; ENANTIOMER; GENE; GENE FUNCTION; GENETIC HETEROGENEITY; GENOME; HUMAN; KARYOTYPE; MUTANT; MUTATION; NEOPLASM; NONHUMAN; ONCOGENE; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; TUMOR GENE; TUMOR SUPPRESSOR GENE;

ANEUPLOIDY; BCR-ABL; BREAKPOINT CLUSTER REGION-ABELSON TYROSINE-PROTEIN KINASE; CD95/FAS; CHROMOSOME INSTABILITY; CLUSTER OF DIFFERENTIATION 95/CELL SURFACE DEATH RECEPTOR; DDR1; DISCOIDIN DOMAIN RECEPTOR TYROSINE KINASE 1; EF1A2; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE; ESPL1; EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 ALPHA; EXTRA SPINDLE POLE BODIES HOMOLOG 1; FGF18; FIBROBLAST GROWTH FACTOR 18; GENETIC HETEROGENEITY; HYAL1/2; HYALURONOGLUCOSAMINIDASE 1/2; IDH1/2; ISOCITRATE DEHYDROGENASES 1/2; KIT; L1M DOMAIN CONTAINING GENE 1; L1MD1; LACTOTRANSFERRIN; LCK; LTF; LYMPHOCYTE-SPECIFIC PROTEIN TYROSINE KINASE; MAPK; MECHANISTIC TARGET OF RAPAMYCIN SERINE/THREONINE KINASE; MITOGEN-ACTIVATED PROTEIN KINASE; MTOR; NAD(P)H DEHYDROGENASE, QUINONE 2; NQO2; PDGFRΒ; PHOSPHATASE AND TENSIN HOMOLOG; PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE, CATALYTIC SUBUNIT ALPHA; PIK3CA; PLETELET DERIVED GROWTH FACTOR RECEPTOR BETA; PTEN; RIBONUCLEASE T2; RNASET2; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1; STAT1; TARGETED THERAPY; TGFB3; TRANSFORMING GROWTH FACTOR, BETA 3; V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG, TYROSINE KINASE RECEPTOR; VHL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR, E3 UBIQUITIN PROTEIN LIGASE; WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 1; WNT1;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; ONCOGENES;

CHAMAELEONIDAE;

EID: 84883805322     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.07.047     Document Type: Review

References (206)

1. Acquati F., et al. Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1104-1109.
2. Ahmadi R., et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J. Neurooncol. 2012, 109:15-22.
3. Ahn Y.H., et al. Map2k4 functions as a tumour suppressor in lung adenocarcinoma and inhibits tumour cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression. Mol. Cell. Biol. 2011, 31:4270-4285.
4. Alhazzazi T.Y., et al. SIRT3 and cancer: tumour promoter or suppressor?. Biochim. Biophys. Acta 2011, 1816:80-88.
5. Anderhub S.J., Krämer A., Maier B. Centrosome amplification in tumourigenesis. Cancer Lett. 2012, 322:8-17.
6. Bachman K.E., Park B.H. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Curr. Opin. Oncol. 2005, 17:49-54.
7. Bagrodia S., Smeal T., Abraham R.T. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. Pigment Cell Melanoma Res. 2012, 25:819-831.
8. Bai Y., et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumours. Cancer Res. 2012, 72:2501-2511.
9. Baldewpersad Tewarie N.M., et al. NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival. Med. Hypotheses 2013, 80:728-731.
10. Baldus S.E., et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010, 16:790-799.
11. Bitton-Worms K., Pikarsky E., Aronheim A. The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol. Cancer 2010, 9:54.
12. Bosch-Presegué L., Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011, 2:648-662.
13. Bralten L.B., et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann. Neurol. 2011, 69:455-463.
14. Breitkopf S.B., et al. Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. J. Proteome Res. 2010, 9:6033-6043.
15. Brosnan J.A., Iacobuzio-Donahue C.A. A new branch on the tree: next-generation sequencing in the study of cancer evolution. Semin. Cell Dev. Biol. 2012, 23:237-242.
16. Bussu F., et al. Immunohistochemical expression patterns of the HER4 receptors in normal mucosa and in laryngeal squamous cell carcinomas: antioncogenic significance of the HER4 protein in laryngeal squamous cell carcinoma. Laryngoscope 2012, 122:1724-1733.
17. Capper D., et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int. J. Cancer 2012, 131:766-768.
18. Chen L.F. Tumour suppressor function of RUNX3 in breast cancer. J. Cell. Biochem. 2012, 113:1470-1477.
19. Chen L., et al. CD95 promotes tumour growth. Nature 2010, 465:492-496.
20. Chen B., et al. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 2012, 7:e42598.
21. Cohen I., et al. Histone modifiers in cancer: friends or foes?. Genes Cancer 2011, 2:631-647.
22. Colombino M., et al. BRAF/NRAS mutation frequencies among primary tumours and metastases in patients with melanoma. J. Clin. Oncol. 2012, 30:2522-2529.
23. Dalerba P., et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol. 2011, 29:1120-1127.
24. D'Antonio M., et al. Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic Acids Res. 2012, 40:978-983.
25. de Melo Maia B., et al. Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside. J. Transl. Med. 2012, 10:150.
26. Deng C.X. SIRT1, is it a tumour promoter or tumour suppressor?. Int. J. Biol. Sci. 2009, 5:147-152.
27. Deng Y.Z., et al. RACK1 suppresses gastric tumourigenesis by stabilizing the β-catenin destruction complex. Gastroenterology 2012, 142:812-823.
28. Di Fiore P.P. Playing both sides: nucleophosmin between tumour suppression and oncogenesis. J. Cell Biol. 2008, 182:7-9.
29. Ding W., et al. NDRG4 is downregulated in glioblastoma and inhibits cell proliferation. OMICS 2012, 16:263-267.
30. Duesberg P., et al. Is carcinogenesis a form of speciation?. Cell Cycle 2011, 10:2100-2114.
31. Duncan C.G., et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012, 22:2339-2355.
32. Durbin A.D., Hannigan G.E., Malkin D. Oncogenic ILK, tumour suppression and all that JNK. Cell Cycle 2009, 8:4060-4066.
33. Dutta K.K., et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci. 2007, 98:1845-1852.
34. Ecker A., et al. The dark and the bright side of Stat3: proto-oncogene and tumour-suppressor. Front. Biosci. 2009, 14:2944-2958.
35. El Ghamrasni S., et al. Inactivation of chk2 and mus81 leads to impaired lymphocytes development, reduced genomic instability, and suppression of cancer. PLoS Genet. 2011, 7:e1001385.
36. Eliseeva I.A., et al. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 2011, 76:1402-1433.
37. Engelmann D., Pützer B.M. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012, 72:571-575.
38. Fernandez A.F., Huidobro C., Fraga M.F. De novo DNA methyltransferases: oncogenes, tumor suppressors, or both?. Trends Genet. 2012, 28:474-479.
39. Ferrando M., et al. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011, 14:467-479.
40. Figueroa M.E., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
41. Finegan K.G., Tournier C. The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res. 2010, 70:5797-5806.
42. Fisher R., Pusztai L., Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 2013, 108:479-485.
43. Fombonne J., et al. Epidermal growth factor triggers an original, caspase-independent pituitary cell death with heterogeneous phenotype. Mol. Biol. Cell 2004, 15:4938-4948.
44. Frederick M.J., et al. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am. J. Pathol. 2011, 178:548-571.
45. Fu Y., et al. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. Biochem. Biophys. Res. Commun. 2011, 410:218-223.
46. Gamper A.M., et al. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumourigenesis. Mol. Cell 2012, 45:233-243.
47. Garcia R., Franklin R.A., McCubrey J.A. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle 2006, 5:1840-1846.
48. Garraway L.A., Jänne P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012, 2:214-226.
49. Gartel A.L. p21(WAF1/CIP1) and cancer: a shifting paradigm?. Biofactors 2009, 35:161-164.
50. Gasch C., et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 2013, 59:252-260.
51. Gerlinger M., et al. Intratumour heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
52. Glick A.B. TGFbeta1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol. Ther. 2004, 3:276-283.
53. Goranova T.E., et al. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumours. Clin. Exp. Metastasis 2011, 28:427-435.
54. Gozé C., et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J. Neurooncol. 2012, 108:69-75.
55. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
56. Greer P.A., Kanda S., Smithgall T.E. The contrasting oncogenic and tumour suppressor roles of FES. Front. Biosci. (Schol. Ed.) 2012, 4:489-501.
57. Guardavaccaro D., Clevers H. Wnt/β-catenin and MAPK signaling: allies and enemies in different battlefields. Sci. Signal. 2012, 5:pe15.
58. Guessous F., et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010, 9:1031-1036.
59. Gullu G., Karabulut S., Akkiprik M. Functional roles and clinical values of insulin-like growth factor binding protein-5 in different types of cancers. Chin. J. Cancer 2012, 31:266-280.
60. Guo S.L., et al. miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int. J. Biol. Sci. 2011, 7:567-574.
61. Haaß W., et al. The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. PLoS One 2012, 7:e42863.
62. Han Y.X., Liang D.Y. The role of the tumour suppressor RUNX3 in giant cell tumour of the bone. Int. J. Oncol. 2012, 40:673-678.
63. Hantschel O., Rix U., Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 2008, 49:615-619.
64. Heinrich R., et al. The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. J. Biol. Chem. 2004, 279:5708-5715.
65. Heng H.H., et al. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J. Cell. Physiol. 2009, 220:538-547.
66. Heng H.H., et al. The evolutionary mechanism of cancer. J. Cell. Biochem. 2010, 109:1072-1084.
67. Heng H.H., et al. Evolutionary mechanisms and diversity in cancer. Adv. Cancer Res. 2011, 112:217-253.
68. Hobbs J., et al. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. Am. J. Surg. Pathol. 2012, 36:1186-1193.
69. Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat. Rev. Cancer 2011, 11:111-121.
70. Humbey O., et al. The ARF tumour suppressor can promote the progression of some tumours. Cancer Res. 2008, 68:9608-9613.
71. Ichimura K. Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathol. 2012, 29:131-139.
72. Irish J.M., et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228.
73. James R.M., et al. K-ras proto-oncogene exhibits tumor suppressor activity as its absence promotes tumorigenesis in murine teratomas. Mol. Cancer Res. 2003, 1:820-825.
74. Jiang C., et al. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2012, 138:637-646.
75. Jin G., et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 2012, 3:774-782.
76. Juratli T.A., et al. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol 2013, 10.1093/neuonc/not006.
77. Kales S.C., et al. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 2010, 70:4789-4794.
78. Kang M.H., et al. Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. Exp. Cell Res. 2011, 317:1746-1762.
79. Kang J.M., et al. CBL enhances breast tumour formation by inhibiting tumour suppressive activity of TGF-β signaling. Oncogene 2012, 31:5123-5131.
80. Kanno T., et al. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene 2012, 31:3098-3110.
81. Kim J.E., et al. Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer 2012, 12:141.
82. Kinney S.R., et al. Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol. Cell. Biol. 2010, 30:4159-4174.
83. Klein G., Imreh S., Zabarovsky E.R. Why do we not all die of cancer at an early age?. Adv. Cancer Res. 2007, 98:1-16.
84. Koivunen P., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488.
85. Koon H.B., et al. FOXP1: a potential therapeutic target in cancer. Expert Opin. Ther. Targets 2007, 11:955-965.
86. Kossatz U., Malek N.P. p27: tumour suppressor and oncogene?. Cell Res. 2007, 17:832-833.
87. Kudo Y., Tsunematsu T., Takata T. Oncogenic role of RUNX3 in head and neck cancer. J. Cell. Biochem. 2011, 112:387-393.
88. Kunnimalaiyaan M., Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?. Anticancer Drugs. 2006, 17:139-142.
89. Kwei K.A., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 27:3635-3640.
90. Lamouille S., Derynck R. Oncogene and tumour suppressor: the two faces of SnoN. EMBO J. 2009, 28:3459-3460.
91. Larsson L.G., Henriksson M.A. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp. Cell Res. 2010, 316:1429-1437.
92. Lazovic J., et al. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol. 2012, 14:1465-1472.
93. Lee J.M. The good oncogene: when bad genes identify good outcome in cancer. Med. Hypotheses 2011, 76:259-263.
94. Lee E.Y., Muller W.J. Oncogenes and tumour suppressor genes. Cold Spring Harb. Perspect. Biol. 2010, 2:a003236.
95. Lee C.W., et al. RUNX3 functions as an oncogene in ovarian cancer. Gynecol. Oncol. 2011, 122:410-417.
96. Lee M.H., et al. Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene 2012, 31:116-127.
97. Li C.G., Eccles M.R. PAX genes in cancer; friends or foes?. Front. Genet. 2012, 3:6.
98. Li Y., et al. PTEN has tumour-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res. 2008, 68:1723-1731.
99. Li H., et al. Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis. PLoS One 2011, 6:e28133.
100. Li S., et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013, 15:57-68.
101. Lian C.G., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
102. Liu H., et al. RNA interference against SPARC promotes the growth of U-87MG human malignant glioma cells. Oncol. Lett. 2011, 2:985-990.
103. Lobry C., Oh P., Aifantis I. Oncogenic and tumour suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 2011, 208:1931-1935.
104. Loeb L.A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer 2011, 11:450-457.
105. Logue J.S., Morrison D.K. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012, 26:641-650.
106. Losman J.A., et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 10.1126/science.1231677.
107. Lu C., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
108. Luo Y., et al. RET is a potential tumour suppressor gene in colorectal cancer. Oncogene 2012, 10.1038/onc.2012.225.
109. Maeda Y., et al. KrasG12D and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J. Clin. Invest. 2012, 122:4388-4400.
110. Majumder S. REST in good times and bad: roles in tumour suppressor and oncogenic activities. Cell Cycle 2006, 5:1929-1935.
111. Manfredi J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumour suppressor. Genes Dev. 2010, 24:1580-1589.
112. Martin M.J., et al. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012, 2:344-355.
113. Martini M., et al. Targeted therapies: how personal should we go?. Nat. Rev. Clin. Oncol. 2011, 9:87-97.
114. McCubrey J.A., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012, 3:1068-1111.
115. McDonald S.L., Silver A. The opposing roles of Wnt-5a in cancer. Br. J. Cancer 2009, 101:209-214.
116. Mehra R., et al. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist. Updat. 2011, 14:260-279.
117. Mendes K.N., et al. Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J. Proteome Res. 2007, 6:2753-2767.
118. Meyer R.D., Husain D., Rahimi N. c-Cbl inhibits angiogenesis and tumour growth by suppressing activation of PLCγ1. Oncogene 2011, 30:2198-2206.
119. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer 2013, http://cgap.nci.nih.gov/Chromosomes/Mitelman. F. Mitelman, B. Johansson, F. Mertens (Eds.).
120. Miyake M., et al. Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol. Rep. 2011, 25:653-660.
121. Mogler C., et al. Heparanase expression in head and neck squamous cell carcinomas is associated with reduced proliferation and improved survival. Histopathology 2011, 58:944-952.
122. Montano N., et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia 2011, 13:1113-1121.
123. Mu L., et al. Favorable outcome associated with an IGF-1 ligand signature in breast cancer. Breast Cancer Res. Treat. 2012, 133:321-331.
124. Navin N., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
125. Niepel M., et al. Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr. Opin. Chem. Biol. 2009, 13:556-561.
126. Niikura N., et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumours. J. Clin. Oncol. 2012, 30:593-599.
127. Oermann E.K., et al. Alterations of metabolic genes and metabolites in cancer. Semin. Cell Dev. Biol. 2012, 23:370-380.
128. Packer L.M., et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 2011, 20:715-727.
129. Pappas J.J., et al. Knockdown of RARB2 identifies a dual role in cancer. Genes Chromosomes Cancer 2011, 50:700-714.
130. Passioura T., et al. N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res. 2005, 65:797-804.
131. Payne S.L., Hendrix M.J., Kirschmann D.A. Paradoxical roles for lysyl oxidases in cancer-a prospect. J. Cell. Biochem. 2007, 101:1338-1354.
132. Pekarsky Y., Croce C.M. Is miR-29 an oncogene or tumour suppressor in CLL?. Oncotarget 2010, 1:224-227.
133. Pelorosso F.G., Balmain A. C/EBPδ: friend or foe? a novel role for C/EBPδ in metastasis. EMBO J. 2010, 29:4063-4065.
134. Perkins N.D. NF-kappaB: tumour promoter or suppressor?. Trends Cell Biol. 2004, 14:64-69.
135. Pool S.E., et al. mTOR Inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer. Cancer Res. 2013, 73:12-18.
136. Puzanov I., Burnett P., Flaherty K.T. Biological challenges of BRAF inhibitor therapy. Mol. Oncol. 2011, 5:116-123.
137. Radhakrishnan S.K., Kamalakaran S. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim. Biophys. Acta 2006, 1766:53-62.
138. Rakheja D., et al. IDH mutations in acute myeloid leukemia. Hum. Pathol. 2012, 2012(43):1541-1551.
139. Ravi R.K., et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J. Clin. Invest. 1998, 101:153-159.
140. Ravi R.K., et al. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J. Cell. Biochem. 1999, 72:458-469.
141. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010, 102:932-941.
142. Reitman Z.J., et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3270-3275.
143. Rikova K., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
144. Robbins D., et al. Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase. Cancer Sci. 2012, 103:1429-1433.
145. Rodriguez F.J., Lewis-Tuffin L.J., Anastasiadis P.Z. E-cadherin's dark side: possible role in tumour progression. Biochim. Biophys. Acta 2012, 1826:23-31.
146. Romagosa C., et al. p16(Ink4a) overexpression in cancer: a tumour suppressor gene associated with senescence and high-grade tumours. Oncogene 2011, 30:2087-2097.
147. Rose A.A., et al. Osteoactivin promotes breast cancer metastasis to bone. Mol. Cancer Res. 2007, 5:1001-1014.
148. Rowland B.D., Peeper D.S. KLF4, p21 and context-dependent opposing forces in cancer. Nat. Rev. Cancer 2006, 6:11-23.
149. Sáinz-Jaspeado M., et al. Caveolin-1 in sarcomas: friend or foe?. Oncotarget 2011, 2:305-312.
150. Sakaizawa K., et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br. J. Cancer 2012, 106:939-946.
151. Sasaki M., et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012, 26:2038-2049.
152. Seltzer M.J., et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70:8981-8987.
153. Seol H., et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 2012, 25:938-948.
154. Serres M.P., et al. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene 2011, 30:2846-2858.
155. Shaulian E. AP-1 - the Jun proteins: oncogenes or tumour suppressors in disguise?. Cell. Signal. 2010, 22:894-899.
156. Shen B., et al. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br. J. Cancer 2012, 106:1486-1494.
157. Shi Q., et al. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene 2007, 26:4084-4094.
158. Shi Q., et al. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumour cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 109:419-424.
159. Shi S., et al. RACK1 promotes non-small-cell lung cancer tumourigenicity through activating sonic hedgehog signaling pathway. J. Biol. Chem. 2012, 287:7845-7858.
160. Shibata T., et al. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 2011, 178:1395-1402.
161. Shimada A., et al. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatr. Blood Cancer 2008, 50:213-217.
162. Sikkema A.H., et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 2009, 2009(69):5987-5995.
163. Song J.Y., et al. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett. 2009, 283:135-142.
164. South A.P., Cho R.J., Aster J.C. The double-edged sword of Notch signaling in cancer. Semin. Cell Dev. Biol. 2012, 23:458-464.
165. Spandidos D.A., et al. Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int. J. Oncol. 2002, 21:237-241.
166. Sporn M.B., Liby K.T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 2012, 12:564-571.
167. Stengel K.R., et al. RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell cycle 2008, 7:1095-1103.
168. Stepanenko A.A., Kavsan V.M. Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory. Biopolym. Cell 2012, 28:267-280.
169. Stepanenko A.A., Kavsan V.M. Immortalization and malignant transformation of eukaryotic cells. Tsitol. Genet. 2012, 2:96-129.
170. Stepanenko A.A., Kavsan V.M. Cancer genes and chromosome instability. Oncogene and Cancer - From Bench to Clinic 2013, 151-182. InTech Publisher.
171. Stevens J.B., et al. Genetic and Epigenetic Heterogeneity in Cancer. eLS 2011, John Wiley & Sons, Ltd., Chichester. 10.1002/9780470015902.a0023592.
172. Stiewe T., Pützer B.M. Role of p73 in malignancy: tumour suppressor or oncogene?. Cell Death Differ. 2002, 9:237-245.
173. Sulzmaier F., Opoku-Ansah J., Ramos J.W. Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter. Small GTPases 2012, 3:173-177.
174. Sun H., et al. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. J. Neurooncol 2013, 10.1007/s11060-013-1107-5.
175. Svensson R.U., Shaw R.J. Cancer metabolism: tumour friend or foe. Nature 2012, 485:590-591.
176. Szerlip N.J., et al. Intratumoural heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3041-3046.
177. Tang B.L. Is Rab25 a tumour promoter or suppressor-context dependency on RCP status?. Tumour Biol. 2010, 31:359-361.
178. Thorner A.R., et al. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One 2010, 5:e13073.
179. Tokumaru Y., et al. The role of PGP9.5 as a tumour suppressor gene in human cancer. Int. J. Cancer 2008, 123:753-759.
180. Tomihari M., et al. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumour-reactive T cells. Cancer Res. 2010, 70:5778-5787.
181. Tront J.S., et al. Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. Cancer Res. 2010, 70:9671-9681.
182. Tsui K.H., et al. Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumourigenesis in prostate carcinoma cells. Prostate 2012, 72:1431-1442.
183. Turcan S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
184. Vangapandu H., Ai W. Kruppel like factor 4 (KLF4): a transcription factor with diverse context-dependent functions. Gene Ther. Mol. Biol. 2009, 13:194-204.
185. Vavouri T., et al. Intrinsic protein disorder and interaction promiscuity are widely associated with dosage sensitivity. Cell 2009, 138:198-208.
186. Villa-Morales M., Fernández-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16:85-101.
187. Wang F., et al. HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro. PLoS One 2008, 3:e3031.
188. Wang L., et al. BMP-2 inhibits tumour growth of human renal cell carcinoma and induces bone formation. Int. J. Cancer 2012, 131:1941-1950.
189. Ward P.S., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
190. Welti J.C., et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 2012, 15:623-641.
191. Wilmott J.S., et al. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br. J. Cancer 2013, 108:924-931.
192. Wu Z.Q., et al. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11312-11317.
193. Xiang J., Wu J. Feud or Friend? The role of the miR-17-92 cluster in tumourigenesis. Curr. Genomics 2010, 11:129-135.
194. Xiang T., et al. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One 2012, 7:e29783.
195. Xiao Z., et al. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: implications for EphB4 as a cancer target. Cancer Biol. Ther. 2012, 13:630-637.
196. Xu W., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
197. Xu X., et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumour. Cell 2012, 148:886-895.
198. Yang L., et al. A tumour suppressor and oncogene: the WT1 story. Leukemia 2007, 21:868-876.
199. Yao J.C., et al. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013, 73:1449-1453.
200. Yurchenko M., Shlapatska L.M., Sidorenko S.P. The multilevel regulation of CD95 signaling outcome. Exp. Oncol. 2012, 34:153-159.
201. Zhang Q., et al. The oncogenic role of Yin Yang 1. Crit. Rev. Oncog. 2011, 16:163-197.
202. Zheng P.P., et al. Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: indication of a significant role of microglia/macrophages in glial tumorigenesis. Cancer Biol. Ther. 2012, 2012(13):836-839.
203. Zhong J., et al. UCHL1 acts as a colorectal cancer oncogene via activation of the β-catenin/TCF pathway through its deubiquitinating activity. Int. J. Mol. Med. 2012, 30:430-436.
204. Zhu Q., et al. Dual role of SnoN in mammalian tumourigenesis. Mol. Cell. Biol. 2007, 27:324-339.
205. Zhu J., et al. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med. Hypotheses 2011, 76:602-603.
206. Zhu J., et al. Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation. J. Mol. Neurosci 2012, 10.1007/s12031-012-9890-6.